-
公开(公告)号：EP1381628A2
公开(公告)日：2004-01-21
申请号：EP02747282.8
申请日：2002-04-16
摘要： The invention relates to novel peptides and partial peptide sequences for the diagnosis and treatment of inflammation and sepsis, said peptides and partial peptide sequences being formed during the inflammation and/or infection of primates and humans, and the use of the same or the use of antibodies formed against said peptides for diagnosis and treatment.
-
12.发明公开Verwendung der Glycin-N-Acyl-Transferase (GNAT) für die Diagnose und Therapie von Entzündungserkrankungen und Sepsis 有权Vernend der der Glycin-N-酰基转移酶（GNAT）fürdie Diagnos vonEntzündungserkrankungenund Sepsis
公开(公告)号：EP1318406A1
公开(公告)日：2003-06-11
申请号：EP01128852.9
申请日：2001-12-04
IPC分类号： G01N33/68 , G01N33/569 , A61P31/04 , A61P37/02
CPC分类号： G01N33/56911 , G01N33/6893 , G01N2333/91057 , G01N2800/26
摘要： Verwendungen der Glycin-N-Acyl-Transferase (GNAT) aus Körperflüssigkeiten oder Körpergeweben in der Human- und Tiermedizin als Markerpeptid zum diagnostischen Nachweis, für die Verlaufsprognose und für die Verlaufskontrolle von Entzündungen und Infektionen und/oder als Target für die therapeutische Beeinflussung des Verlaufs von Entzündungen und/oder Infektionen.
摘要翻译： 在人或兽医学中使用来自体液或组织的甘氨酸-N-酰基转移酶（GNAT）作为标记肽，用于诊断，预后或监测炎症或感染的进展和/或作为这些的治疗靶标 条件是新的。 还包括独立权利要求：（1）脓毒症或严重感染的特异性诊断（早期）检测，特别是败血症样全身感染，其包括：（a）确定存在或 生物流体样品中GNAT的量; （b）得出关于脓毒症或感染的存在及其可能的进展，严重性和/或治疗结果的结论; （2）使用GNAT预防或治疗炎性疾病和感染，包括败血症; （3）用于治疗（全身）炎症的药物组合物，包括：（a）GNAT或其肽片段和载体; 或（B）抗GNAT，其片段或加工形式的抗体（Ab）和载体; （4）包含固相的免疫吸附剂，用于选择性结合GNAT与血液循环，用于治疗炎症和败血症。
-
公开(公告)号：EP1318403A1
公开(公告)日：2003-06-11
申请号：EP01128849.5
申请日：2001-12-04
IPC分类号： G01N33/68 , G01N33/569
CPC分类号： G01N33/6893 , G01N33/56911 , G01N2800/26
摘要： Verfahren zur differentialdiagnostischen Früherkennung und Erkennung, für die Verlaufsprognose und die Beurteilung des Schweregrads und zur therapiebegleitenden Verlaufsbeurteilung von Sepsis und sepsisähnlichen systemischen Infektionen, bei dem man, vorzugsweise unter Bestimmung mindestens eines weiteren für die Sepsisdiagnose geeigneten Parameters, die Menge von S100B in einer biologischen Flüssigkeit eines Patienten, bei dem eine Sepsis vorliegt oder ein Verdacht auf Sepsis besteht, bestimmt und aus der bestimmten Menge an S100B Schlüsse hinsichtlich des Vorliegens, des zu erwartenden Verlaufs, des Schweregrads und/oder des Erfolgs eingeleiteter Maßnahmen zur Therapie der Sepsis zieht.
摘要翻译： 差异诊断早期识别的方法，预后的判断和败血症的严重程度和治疗要求的估计以及类似的全身感染包括利用在来自人败血症患者（或疑似败血症）的生物流体中测定参数S100B中获得的结果 患者）。
-
公开(公告)号：EP0968427B1
公开(公告)日：2003-06-04
申请号：EP98922615.4
申请日：1998-03-11
发明人： STRUCK, Joachim
IPC分类号： G01N33/564
CPC分类号： G01N33/78 , G01N33/564 , G01N2800/24 , Y10S435/973
摘要： The invention relates to a method for detecting thyroid autoantibodies in a biological sample taken from a patient in the context of differential diagnosis of diseases associated with changes in and/or malfunctions of the thyroid. The process of detecting the presence and/or quantity of thyroid autoantibodies in the sample uses an immunodiagnostic method of detection whereby a measurement signal is provided per detection. Said measurement signal generally represents the presence and quantity of at least two antibodies, including anti-TPO-autoantibodies and anti-Tg-autoantibodies, in the sample. Said method increases the selectivity and sensitivity of the detection of autoantibodies typical for certain autoimmune diseases whilst simplifying the process.
-
-
公开(公告)号：EP2028493B1
公开(公告)日：2010-07-28
申请号：EP08075749.5
申请日：1999-10-13
IPC分类号： G01N33/74 , C07K14/585 , A61K38/23 , A61K38/22
CPC分类号： G01N33/74 , C07K14/585 , G01N2333/585
-
17.发明授权METHOD FOR THE SELECTIVE DETERMINATION OF PROCALCITONIN 1-116 FOR DIAGNOSTIC PURPOSES AND ANTIBODIES AND KITS FOR CARRYING OUT SUCH A METHOD 有权选择性确定用于诊断目的的促肾上腺皮质素1-116的方法以及实施这种方法的抗体和试剂盒
公开(公告)号：EP2032992B1
公开(公告)日：2009-08-26
申请号：EP08715933.1
申请日：2008-02-21
发明人： BERGMANN, Andreas , STRUCK, Joachim
IPC分类号： G01N33/74 , C07K16/26 , C07K14/585
CPC分类号： G01N33/6854 , C07K16/26 , C07K2317/34 , G01N33/74 , G01N2333/585
摘要： Immunoassay for procalcitonin in a biological sample from a patient comprises selectively determining full-length procalcitonin 1-116 with alanine and proline at positions 1 and 2. An independent claim is also included for an antibody that selectively binds to procalcitonin 1-116.
摘要翻译： 用于确定患者生物样品中降钙素原和降钙素原衍生物用于诊断目的的免疫诊断方法，特别是用于监测和控制局部或全身细菌感染，炎症，败血症或神经退行性疾病的治疗和监测进程 ，其中在完整降钙素原1-116（SEQ ID NO：1）的氨基末端的1和2位具有氨基酸丙氨酸和脯氨酸（Ala-Pro，AP）的那些分子形式的降钙素原或降钙素原部分肽 NO：1）被选择性地确定，并且用于实施这种方法的抗体和试剂盒。
-
18.发明公开IN VITRO VERFAHREN ZUR ERKENNUNG UND FRÜHERKENNUNG UND ZUR BEGLEITENDEN KONTROLLE DER THERAPIE VON ARZNEI- UND SUCHTMITTELINDUZIERTEN LEBERSCHÄDEN 有权体外方法进行检测和早期发现和治疗随附的制药的控制权，并寻求资金引起的肝损害
公开(公告)号：EP2016416A2
公开(公告)日：2009-01-21
申请号：EP07724987.8
申请日：2007-05-08
IPC分类号： G01N33/574 , G01N33/576 , G01N33/68
CPC分类号： G01N33/6893 , G01N2800/085
摘要： In vitro method for the identification and early identification and for the concomitant monitoring of the therapy and cure of in particular drug-induced or addictive substance-induced liver damage, in which the occurrence of the human enzyme carbamoyl synthase 1 (CPS 1) or its concentration is determined in serum or plasma samples from patients who are being or have been treated with potentially liver-damaging drugs, or from people who take harmful stimulants and addictive substances or are exposed to hepatotoxic substances.
-
公开(公告)号：EP1399476B1
公开(公告)日：2006-08-16
申请号：EP02745379.4
申请日：2002-06-12
IPC分类号： C07K14/47 , G01N33/569 , G01N33/68
CPC分类号： C07K14/4741 , G01N33/6893 , G01N2333/4742 , G01N2800/26
摘要： The invention relates to the use of novel soluble cytokeratine-1 fragments from body fluids or tissues a marker peptides for the diagnostic detection of the course prognosis and course control of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
-
20.发明授权VERFAHREN ZUR SEPSISDIAGNOSE DURCH BESTIMMUNG VON ANTI-ASIALO-GANGLIOSID-ANTIKÖRPERN 有权方法脓毒症诊断中测定抗唾液酸神经节苷脂抗体作者：
公开(公告)号：EP1514113B1
公开(公告)日：2006-08-09
申请号：EP03755925.9
申请日：2003-04-02
发明人： BERGMANN, Andreas
IPC分类号： G01N33/564 , G01N33/569 , G01N33/68
CPC分类号： G01N33/6854 , G01N2400/50 , G01N2405/10 , G01N2500/00 , G01N2800/52
摘要： The invention relates to a method for the early detection and detection, the progression prognosis and the evaluation of the degree of severity, and the treatment-accompanying progression evaluation of sepsis and sepsis-like systemic infections, and for the estimation of the danger which would be presented to patients at high risk of sepsis, by the development of a sepsis. According to the inventive method, the presence and/or quantity of anti-asialo-GM1 antibodies (anti-AGM1 antibodies), and antibodies which cross-react with the same, in a biological liquid of a patient or a patient at high risk of sepsis is determined, and conclusions are drawn from the presence and/or quantity of the same in terms of presence, expected progression, degree of severity or the success of a treatment for the inflammatory disease or sepsis, or in terms of the danger presented to a patient at high risk of sepsis. The inventive method enables potentially harmful banked blood to be eliminated if donor blood is used.
-
-
-
-
-
-
-
-
-
搜索结果
79 条记录 (耗时 0.016 秒)
